Anidulafungin, VER002

DRUG3 trials

Sponsors

Pfizer

Conditions

AspergillosisCandidiasis

Phase 2

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

CompletedNCT00037219

PfizerCandidiasis

Start: 2001-08-31End: 2002-11-30Updated: 2008-10-21

A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

CompletedNCT00037206

PfizerAspergillosis

Start: 2002-05-31End: 2003-02-28Updated: 2008-10-21

The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)

CompletedNCT00041704

PfizerCandidiasis

Start: 2002-08-31End: 2004-08-31Updated: 2008-10-20